New Elite Feature: Chart Magnifying Glass

Monopar Therapeutics Inc.

Contributing Author

Recent Articles by Monopar Therapeutics Inc.

5 hours	Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease MNPR GlobeNewswire
Jun-01	Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 MNPR GlobeNewswire
May-19	Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease MNPR +17.66% MNPR GlobeNewswire
May-14	Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates MNPR GlobeNewswire
Apr-19	Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 MNPR GlobeNewswire
Mar-27	Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update MNPR GlobeNewswire
Mar-02	Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer MNPR GlobeNewswire
Nov-13	Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments MNPR +5.36% GlobeNewswire
Nov-09	Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting 2025 MNPR GlobeNewswire
Oct-15	Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting 2025 MNPR -5.11% GlobeNewswire
Sep-23	Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants MNPR +7.94% GlobeNewswire
Sep-23	Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients MNPR +7.94% GlobeNewswire
Sep-14	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting MNPR GlobeNewswire
Sep-03	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting MNPR +6.72% GlobeNewswire
Aug-12	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments MNPR +14.55% GlobeNewswire
Jun-11	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers MNPR GlobeNewswire
Jun-03	Monopar Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes MNPR +7.00% GlobeNewswire
May-13	Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments MNPR GlobeNewswire
May-07	Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 MNPR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)